Authors: Mountfield, RJ Senepin, S Schleimer, M Walter, I Bittner, B

Citation: Rj. Mountfield et al., Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450, INT J PHARM, 211(1-2), 2000, pp. 89-92

Authors: Bittner, B Thelly, T Isel, H Mountfield, RJ

Citation: B. Bittner et al., The impact of co-solvents and the composition of experimental formulationson the pump rate of the ALZET (R) osmotic pump, INT J PHARM, 205(1-2), 2000, pp. 195-198

Authors: Schulz-Utermoehl, T Mountfield, RJ Madsen, K Jorgensen, PN Hansen, KT

Citation: T. Schulz-utermoehl et al., Selective and potent inhibition of human CYP2C19 activity by a conformationally targeted antipeptide antibody, DRUG META D, 28(7), 2000, pp. 715-717

Authors: Schulz-Utermoehl, T Mountfield, RJ Bywater, RP Madsen, K Jorgensen, PN Hansen, KT

Citation: T. Schulz-utermoehl et al., Structure-function analysis of human CYP3A4 using a specific proinhibitoryantipeptide antibody, DRUG META D, 28(7), 2000, pp. 718-725

Authors: Mountfield, RJ Kiehr, B John, BA

Citation: Rj. Mountfield et al., Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat, DRUG META D, 28(5), 2000, pp. 503-513

Authors: Mountfield, RJ Panduro, AM Wassmann, O Thompson, M John, B van der Merbel, N

Citation: Rj. Mountfield et al., Metabolism of levormeloxifene, a selective oestrogen receptor modulator, in the Sprague-Dawley rat, Cynomolgus monkey and postmenopausal woman, XENOBIOTICA, 30(2), 2000, pp. 201-217